Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Gabrielle Sulzberger, a director at Eli Lilly, acquired 11 shares of common stock through a deferral plan.

Summary

• Gabrielle Sulzberger, a director at Eli Lilly & Co, acquired 11 shares of common stock on September 16, 2024.
• The shares were acquired at a price of $923.54 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock following Ms. Sulzberger's separation from service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director's continued investment in the company, but it is a routine transaction.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the director's separation from service.

Industry Context

Director share acquisitions are a common occurrence and are often seen as a sign of confidence in the company's future prospects. This is a routine transaction and does not indicate any significant change in the company's operations or outlook.

Comparison to Industry Standards

• Director share acquisitions are a common practice across publicly traded companies, including pharmaceutical companies like Pfizer (PFE) and Johnson & Johnson (JNJ).
• These transactions are typically part of compensation packages or deferral plans, and are not unusual.
• The size of the acquisition, 11 shares, is relatively small and likely part of a regular compensation plan.

Stakeholder Impact

• The share acquisition has a minor positive impact on shareholders as it indicates director confidence in the company.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Units, Form 4, LLY